Sales & Marketing News | pharmaphorum

News

A giemsa stained blood smear from a person with beta thalassaemia

First CRISPR drug Casgevy gets swift second approval

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-

News

Roche bags EU okay for subcutaneous Tecentriq

Roche has been given EU approval for a new formulation of its cancer immunotherapy Tecentriq that aims to make dosing easier for patients, nurses, and physicians.

News

Michael Vassiladis, chairman of the IG BCE union

German union will resist any plan to split up Bayer

One of Germany’s main trade unions has pushed back against any future break-up of pharmaceutical and agrochemicals giant Bayer, claiming such a move would put thousands of

News

As Novartis backs off, Amgen said to be after Cytokinetics

Speculation about a takeover play for Cytokinetics isn’t going away, with Amgen the latest company to be linked to the company and its highly-anticipated cardiovascular dr

News

Santhera debuts DMD drug Agamree in Germany

Santhera’s new treatment for Duchenne muscular dystrophy Agamree has been launched in its first market, Germany, following its EU approval last month.

News

Keytruda breaks new ground in cervical cancer

MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/

First CRISPR drug Casgevy gets swift second approval

Roche bags EU okay for subcutaneous Tecentriq

German union will resist any plan to split up Bayer

As Novartis backs off, Amgen said to be after Cytokinetics

Santhera debuts DMD drug Agamree in Germany

Keytruda breaks new ground in cervical cancer

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks